JBT MAREL Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that JBT MAREL Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.80B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.72B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $1.66B | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $1.59B | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $1.87B | Feb 23, 2023 |
| FY2022 | Dec 31, 2020 | $1.73B | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $545.50M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $489.40M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $493.30M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $417.50M | Mar 2, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.80B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.72B | Mar 2, 2026 |
| FY2023 | Dec 31, 2023 | $444.60M | Feb 23, 2024 |
| FY2023 | Sep 30, 2023 | $403.60M | Feb 23, 2024 |
| FY2023 | Jun 30, 2023 | $427.70M | Feb 23, 2024 |
| FY2023 | Mar 31, 2023 | $388.50M | Feb 23, 2024 |
| FY2023 | Dec 31, 2022 | $441.20M | Feb 23, 2024 |
| FY2023 | Sep 30, 2022 | $398.80M | Feb 23, 2024 |
| FY2023 | Jun 30, 2022 | $394.00M | Feb 23, 2024 |
| FY2023 | Mar 31, 2022 | $356.30M | Feb 23, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $255.00M | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | $219.60M | Feb 23, 2023 |
| FY2022 | Dec 31, 2020 | $223.50M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $263.60M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $233.60M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $189.80M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $158.30M | Feb 28, 2019 |
| FY2017 | Dec 31, 2015 | $123.60M | Feb 28, 2018 |
| FY2016 | Dec 31, 2014 | $102.70M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $91.30M | Feb 29, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($50.50M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $85.40M | Mar 2, 2026 |
| FY2023 | Dec 31, 2023 | $81.10M | Feb 23, 2024 |
| FY2023 | Sep 30, 2023 | $441.60M | Feb 23, 2024 |
| FY2023 | Jun 30, 2023 | $32.70M | Feb 23, 2024 |
| FY2023 | Mar 31, 2023 | $27.20M | Feb 23, 2024 |
| FY2023 | Dec 31, 2022 | $41.00M | Feb 23, 2024 |
| FY2023 | Sep 30, 2022 | $36.30M | Feb 23, 2024 |
| FY2023 | Jun 30, 2022 | $34.40M | Feb 23, 2024 |
| FY2023 | Mar 31, 2022 | $25.70M | Feb 23, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $189.40M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $118.40M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $164.70M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $132.60M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $125.60M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $163.10M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $188.20M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $143.80M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $143.80M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $101.00M | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.30M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $20.90M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $20.50M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $23.00M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $22.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $29.30M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $28.50M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $26.90M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $28.70M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $23.60M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $409.60M | Feb 23, 2024 |
| FY2023 | Dec 31, 2022 | $389.70M | Feb 23, 2024 |
| FY2023 | Dec 31, 2021 | $351.40M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $358.50M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $396.40M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $346.80M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $325.20M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $267.40M | Feb 28, 2019 |
| FY2017 | Dec 31, 2015 | $207.00M | Feb 28, 2018 |
| FY2016 | Dec 31, 2014 | $183.30M | Feb 28, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $142.30M | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | $225.70M | Feb 23, 2023 |
| FY2022 | Dec 31, 2020 | $252.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $110.20M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $153.90M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $104.60M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $67.40M | Feb 28, 2019 |
| FY2017 | Dec 31, 2015 | $111.90M | Feb 28, 2018 |
| FY2016 | Dec 31, 2014 | $77.70M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $62.00M | Feb 29, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.19B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $3.41B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $2.71B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $2.64B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $2.14B | Feb 23, 2023 |
| FY2022 | Dec 31, 2020 | $1.81B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $1.91B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $1.44B | Feb 25, 2021 |
| FY2018 | Jan 1, 2018 | $1.47B | Feb 28, 2019 |
| FY2019 | Dec 31, 2017 | $1.39B | Mar 2, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.46B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.54B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $1.49B | Mar 2, 2026 |
| FY2025 | Dec 31, 2022 | $905.40M | Mar 2, 2026 |
| FY2024 | Dec 31, 2021 | $786.50M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $672.40M | Feb 23, 2024 |
| FY2022 | Dec 31, 2019 | $569.50M | Feb 23, 2023 |
| FY2021 | Dec 31, 2018 | $456.90M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $441.90M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $179.90M | Mar 2, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.43B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $769.10M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $779.50M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $770.10M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $646.70M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $543.90M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $528.90M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $321.40M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $301.80M | Mar 2, 2020 |
| FY2018 | Feb 24, 2017 | $75 | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.46B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.54B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $1.46B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $894.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $733.40M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $627.80M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $532.80M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $416.50M | Mar 2, 2020 |
| FY2018 | Jan 1, 2018 | $303.50M | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | $333.70M | Feb 28, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $167.90M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.23B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $483.30M | Mar 2, 2026 |
| FY2023 | Dec 31, 2022 | $71.70M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $78.80M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $47.50M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $39.50M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $43.00M | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | $34.00M | Mar 2, 2020 |
| FY2019 | Dec 31, 2016 | $33.20M | Mar 2, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.47B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.25B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $646.40M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $977.30M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $674.40M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $522.50M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $698.30M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $387.10M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $372.60M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $491.60M | Feb 28, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Mar 2, 2026 |
| FY2023 | Dec 31, 2023 | 2 | Feb 23, 2024 |
| FY2023 | Sep 30, 2023 | 13 | Feb 23, 2024 |
| FY2023 | Jun 30, 2023 | 1 | Feb 23, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Feb 23, 2024 |
| FY2023 | Dec 31, 2022 | 1 | Feb 23, 2024 |
| FY2023 | Sep 30, 2022 | 1 | Feb 23, 2024 |
| FY2023 | Jun 30, 2022 | 1 | Feb 23, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Feb 23, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Mar 2, 2026 |
| FY2023 | Dec 31, 2023 | 2 | Feb 23, 2024 |
| FY2023 | Sep 30, 2023 | 13 | Feb 23, 2024 |
| FY2023 | Jun 30, 2023 | 1 | Feb 23, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Feb 23, 2024 |
| FY2023 | Dec 31, 2022 | 1 | Feb 23, 2024 |
| FY2023 | Sep 30, 2022 | 1 | Feb 23, 2024 |
| FY2023 | Jun 30, 2022 | 1 | Feb 23, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Feb 23, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | 31.84M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 31.79M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 31.80M | Feb 23, 2024 |
| FY2021 | Dec 31, 2020 | 31.73M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 31.67M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 31.52M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 31.58M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 29.16M | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | 29.15M | Feb 28, 2017 |
| FY2015 | Dec 31, 2014 | 29.09M | Feb 29, 2016 |